Dr. Peter G. Rose, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 326
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OH license 35049163
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Hillcrest Hospital Mayfield Heights, OH
- Fairview Hospital Cleveland, OH
- Euclid Hospital Euclid, OH
- Ashtabula County Medical Center Ashtabula, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 326
- Services billed
- 960
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 364 | 81 |
| Established patient office or other outpatient visit, 20-29 minutes | 191 | 165 |
| Established patient office or other outpatient visit, 10-19 minutes | 160 | 147 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 124 | 39 |
| New patient office or other outpatient visit, 30-44 minutes | 37 | 37 |
| Telephone medical discussion with physician, 5-10 minutes | 30 | 24 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 13 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 14 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Zejula (niraparib tosylate) | 34 |
| Lenvima (lenvatinib mesylate) | 17 |
| Letrozole Other prescribers in Cleveland, OH | 15 |
| Anastrozole Other prescribers in Cleveland, OH | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $121 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $121 |
|---|
| Food and Beverage | $121 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 8 companies. The companies reported $59,917 in research payments for these studies, mostly to the institutions running them.
- SURPASS 3
Adaptimmune LLC - Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
AbbVie Inc. · Completed · NCT05041257 - RAMP 201 - GOG-3052
Verastem, Inc. - A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Pharmaand GmbH · Active, not recruiting · NCT03522246 - ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with a germline BRCA mutation and Stage III-IV Ovarian Cancer who are in Complete or Parti…
AstraZeneca Pharmaceuticals LP - A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer.
Genmab U.S., Inc. - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248 - A randomized openlabel phase 3 trial of tisotumab vedotin vs investigators choice chemotherapy in second or thirdline recurrent or metastatic cervical cancer
Pfizer Inc. - Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab U.S., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.